Table 1.
Demographic and baseline characteristics of study participants (n = 234)
| Characteristics | DCF (n = 119) | CF (n = 115) | Total (n = 234) |
|---|---|---|---|
| Male sex | 81 (68.1 %) | 88 (76.5 %) | 169 (72.2 %) |
| Age | |||
| Median (years)a | 56.6 (19–80) | 55.5 (33–74) | 56.1 (19–80) |
| <65 years | 99 (83.2 %) | 96 (83.5 %) | 195 (83.3 %) |
| ≥65 years | 20 (16.8 %) | 19 (16.5 %) | 39 (16.7 %) |
| Duration of gastric cancer (months) | |||
| Meanb | 8.82 (18.25) | 6.89 (13.70) | 7.87 (16.17) |
| Medianc | 0.69 (0–124.3) | 0.62 (0–64.4) | 0.68 (0–124.3) |
| KPS | |||
| ≥80 | 115 (96.6 %) | 108 (93.9 %) | 223 (95.3 %) |
| <80 | 4 (3.4 %) | 7 (6.1 %) | 11 (4.7 %) |
| Weight loss in prior 3 months | |||
| ≤5 % | 70 (58.8 %) | 65 (56.5 %) | 135 (57.7 %) |
| 5–10 % | 28 (23.5 %) | 28 (24.3 %) | 56 (23.9 %) |
| >10 % | 21 (17.6 %) | 22 (19.1 %) | 43 (18.4 %) |
| Primary tumor site | |||
| Gastroesophageal junction | 20 (16.8 %) | 29 (25.2 %) | 49 (20.9 %) |
| Fundus | 12 (10.1 %) | 9 (7.8 %) | 21 (9.0 %) |
| Antrum | 44 (37.0 %) | 41 (35.7 %) | 85 (36.3 %) |
| Body | 43 (36.1 %) | 37 (32.2 %) | 80 (34.2 %) |
| Other | 13 (10.9 %) | 6 (5.2 %) | 19 (8.1 %) |
| Unknown | 1 (0.8 %) | 2 (1.7 %) | 3 (1.3 %) |
| Disease status | |||
| Recurrent | 30 (25.2 %) | 26 (22.6 %) | 56 (23.9 %) |
| Metastatic | 89 (74.8 %) | 89 (77.4 %) | 178 (76.1 %) |
| Histology | |||
| Adenocarcinoma | |||
| Moderate differentiation | 19 (16.0 %) | 18 (15.7 %) | 37 (15.8 %) |
| Moderate–low differentiation | 6 (5.0 %) | 8 (7.0 %) | 14 (6.0 %) |
| Low differentiation | 60 (50.4 %) | 55 (47.8 %) | 115 (49.1 %) |
| Unknown differentiation | 25 (21.0 %) | 27 (23.5 %) | 52 (22.2 %) |
| Signet ring cell cancer | 20 (16.8 %) | 15 (13.0 %) | 35 (15.0 %) |
| Mucous adenocarcinoma | 3 (2.5 %) | 4 (3.5 %) | 7 (3.0 %) |
| Other | 1 (0.8 %) | 1 (0.9 %) | 2 (0.9 %) |
| AJCC staging | |||
| III | 5 (4.2 %) | 2 (1.7 %) | 7 (3.0 %) |
| IV | 113 (95.0 %) | 112 (97.4 %) | 225 (96.2 %) |
| Unknown | 0 | 1 (0.9 %) | 1 (0.4 %) |
| No. of organs involved | |||
| 1 | 52 (43.7 %) | 56 (48.7 %) | 108 (46.2 %) |
| 2 | 37 (31.1 %) | 42 (36.5 %) | 79 (33.8 %) |
| >2 | 28 (23.5 %) | 16 (13.9 %) | 44 (18.8 %) |
| Prior therapy | |||
| Radiotherapy | 1 (0.8 %) | 0 | 1 (0.4 %) |
| Surgery | 46 (38.7 %) | 39 (33.9 %) | 85 (36.3 %) |
| Palliative | 9 (19.6 %) | 10 (25.6 %) | 19 (22.4 %) |
| Curative | 30 (65.2 %) | 27 (69.2 %) | 57 (67.1 %) |
| Other | 7 (15.2 %) | 2 (5.1 %) | 9 (10.6 %) |
| Chemotherapyd | 23 (19.3 %) | 22 (19.2 %) | 45 (19.2 %) |
AJCC American Joint Committee on Cancer, CF cisplatin and 5-fluorouracil, DCF docetaxel, cisplatin, and 5-fluorouracil, HR hazard ratio, KPS Karnofsky performance status
aThe range (years) is given in parentheses.
bThe standard deviation is given in parentheses.
cThe range (months) is given in parentheses.
dAdjuvant/neoadjuvant